ENIXUM <sup>®</sup> IS BIOEQUIVALENT ANTITHROMBOTICS TO CLEXANE <sup>®</sup> (by the results of open comparative randomized multicenter clinical trial of Enixum® and Clexane <sup>®</sup> efficacy and safety)
Open comparative randomized multicenter clinical trial of low molecular weight heparins Enixum® and Clexane <sup>®</sup> efficacy and safety included 56 patients with high risk of thrombotic and thromboembolic complications after hip or knee replacement. Results demonstrated identical efficacy, safety and tolerability for both Enixum <sup>®</sup> and Clexane <sup>®</sup>. Together with literature data the obtained results confirmed that risk/benefit ratio in this study can be considered acceptable for trial participants. New low molecular heparin Enixum <sup>®</sup> will expand enoxaparin sodium market in Russia, improve competition in this area and provide hospitals with modern effective and safe antithrombotics.